Genetic ablation or pharmacological inhibition of SLC7A11 via erastin, imidazole ketone erastin, sulfasalazine, or sorafenib rapidly decreases the level of GSH and confers to ferroptosis.[1, 48, 49, 50] Whereas sorafenib acts as a clinical drug to efficiently inhibit liver cancer development via inactivation of SLC7A11, the clinical compound identified to prevent tissue injury via activation of SLC7A11 is little known. Here, SLC7A11 is linked to liver cancer.